Skip to main content

ResMed| stock price and financials

  • RMD · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$239.53+0.27%Close 13 Nov 2026
EV / EBITDA
15.94
Beta · 1 year
0.49
Return · 1 year
−5.3%
52-week range$180.27 — $277.67

Share price close 16 Nov 2026

−0.4%1 monthHigh $253.20Low $227.08
$220$230$240$250$260Q1 FY2027 report filed 30 Oct 202623 Oct29 Oct4 Nov10 Nov16 Nov
+19.5%6 monthsHigh $253.20Low $182.82
$180$200$220$240$260Q4 FY2026 report filed 13 Aug 2026Q1 FY2027 report filed 30 Oct 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+0.2%year to dateHigh $275.96Low $182.82
$175$200$225$250$275$300Q2 FY2026 report filed 30 Jan 2026Q3 FY2026 report filed 1 May 2026Q4 FY2026 report filed 13 Aug 2026Q1 FY2027 report filed 30 Oct 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
−1.3%1 yearHigh $275.96Low $182.82
$175$200$225$250$275$300Q2 FY2026 report filed 30 Jan 2026Q3 FY2026 report filed 1 May 2026Q4 FY2026 report filed 13 Aug 2026Q1 FY2027 report filed 30 Oct 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26
+58.6%3 yearsHigh $293.73Low $148.90
$100$150$200$250$300Q2 FY2024 report filed 25 Jan 2024Q3 FY2024 report filed 26 Apr 2024Q4 FY2024 report filed 9 Aug 2024Q1 FY2025 report filed 25 Oct 2024Q2 FY2025 report filed 31 Jan 2025Q3 FY2025 report filed 24 Apr 2025Q4 FY2025 report filed 8 Aug 2025Q1 FY2026 report filed 31 Oct 2025Q2 FY2026 report filed 30 Jan 2026Q3 FY2026 report filed 1 May 2026Q4 FY2026 report filed 13 Aug 2026Q1 FY2027 report filed 30 Oct 2026Apr 24Sep 24Feb 25Aug 25Jan 26Jun 26Nov 26
+312%10 yearsHigh $295.80Low $59.03
$0$100$200$300Apr 18Sep 19Feb 21Jul 22Jan 24Jun 25Nov 26

Quarterly or annual report filed

In one paragraph

ResMed| reported revenue of $5.65 billion for fiscal year 2026 (the twelve months to 30 Jun 2026), up 9.9% from fiscal 2025. Net income was $1.52 billion and diluted earnings per share $10.43.

In its latest reported quarter, the first quarter of fiscal 2027 (the three months to 30 Sep 2026), revenue was $1.41 billion, up 5.9% from a year earlier.

Figures from ResMed|'s annual and quarterly reports, compiled and checked by AapWire. Latest report filed 30 Oct 2026.

Revenue FY2026
$5.65B+9.9%
Net income
$1.52B+8.8%
Diluted EPS
$10.43+9.7%
Gross margin
61.1%+1.7 pts
Free cash flow
$1.65B−0.7%
Net cash
$643.3M

Fiscal 2026 against fiscal 2025; bars show the last 10 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2017–2026

  • Revenue
  • Net income
$0$2B$4B$6BRevenue, FY17: $2.07BNet income, FY17: $342.28MFY17Revenue, FY18: $2.34BNet income, FY18: $315.59MFY18Revenue, FY19: $2.61BNet income, FY19: $404.59MFY19Revenue, FY20: $2.96BNet income, FY20: $621.67MFY20Revenue, FY21: $3.2BNet income, FY21: $474.5MFY21Revenue, FY22: $3.58BNet income, FY22: $779.44MFY22Revenue, FY23: $4.22BNet income, FY23: $897.56MFY23Revenue, FY24: $4.69BNet income, FY24: $1.02BFY24Revenue, FY25: $5.15BNet income, FY25: $1.4BFY25Revenue, FY26: $5.65BNet income, FY26: $1.52BFY26

Latest quarter · Q1 FY2027 to 30 Sep 2026, filed 30 Oct 2026 · Full results →

Revenue
$1.41B+5.9% on a year
Gross margin
61.5%+0.3 pts on a year
Operating income
$453.0M+1.4% on a year
Net income
$418.4M+20.0% on a year
Diluted EPS
$2.92+23.2% on a year
Free cash flow
$373.7M−9.8% on a year

Comparable companies All of Health Care →

ResMed| beside the other S&P 500 members in Health Care Equipment, by market value.

ResMed| and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
ResMed|RMD—+0.3%−5.3%———
Abbott LaboratoriesABT$188.1B+1.2%−15.8%+10.0%9.7%40.0
Intuitive SurgicalISRG$152.6B+0.8%−22.5%+20.5%25.5%51.6
Boston ScientificBSX$63.86B+0.3%−57.4%+8.9%16.6%18.2
Edwards LifesciencesEW$61.47B+1.3%+25.2%+13.4%15.3%60.2
Becton DickinsonBDX$59.14B+1.1%+44.4%−2.6%4.5%62.9
Idexx LaboratoriesIDXX$55.78B+0.9%−1.3%+11.9%25.4%47.2

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2017–2026

  • Gross
  • Operating
  • Net
0%25%50%75%61.1%33.4%26.9%FY17FY20FY23FY26

ResMed| revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By segment

ResMed| revenue by segment, by fiscal year
RevenueFY 2022FY 2023FY 2024FY 2025FY 2026
Total Sleep and Breathing Health$3.18B$3.73B+17.2%$4.10B+10.1%$4.50B+9.8%$4.98B+10.5%
Residential Care Software$400.8M$498.0M+24.2%$584.1M+17.3%$641.4M+9.8%$675.8M+5.4%
Total revenue$3.58B$4.22B$4.69B$5.15B$5.65B

By product

ResMed| revenue by product, by fiscal year
RevenueFY 2022FY 2023FY 2024FY 2025FY 2026
Total Sleep and Breathing Health$3.18B$3.73B+17.2%$4.10B+10.1%$4.50B+9.8%$4.98B+10.5%
Residential Care Software$400.8M$498.0M+24.2%$584.1M+17.3%$641.4M+9.8%$675.8M+5.4%
Total revenue$3.58B$4.22B$4.69B$5.15B$5.65B

By region

ResMed| revenue by region, by fiscal year
RevenueFY 2022FY 2023FY 2024FY 2025FY 2026
United States$2.25B$2.72B+20.9%$2.98B+9.6%$3.29B+10.3%$3.56B+8.4%
Rest of the World$1.33B$1.50B+13.1%$1.71B+13.5%$1.86B+9.1%$2.09B+12.4%
Total revenue$3.58B$4.22B$4.69B$5.15B$5.65B

Financial statements

Fiscal years, the latest ending 30 Jun 2026. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

ResMed| income statement, annual
PeriodFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Revenue$2.07B$2.34B$2.61B$2.96B$3.20B$3.58B$4.22B$4.69B$5.15B$5.65B
Revenue growth+12.4%+13.2%+11.4%+13.4%+8.1%+11.9%+18.0%+10.9%+9.8%+9.9%
Gross profit$1.20B$1.33B$1.49B$1.72B$1.84B$2.02B$2.36B$2.66B$3.05B$3.45B
Operating income$425.8M$541.8M$579.3M$809.7M$903.7M$1.00B$1.13B$1.32B$1.69B$1.89B
Net income$342.3M$315.6M$404.6M$621.7M$474.5M$779.4M$897.6M$1.02B$1.40B$1.52B
Diluted EPS$2.40$2.19$2.80$4.27$3.24$5.30$6.09$6.92$9.51$10.43
Gross margin58.1%57.0%57.3%58.1%57.5%56.6%55.8%56.7%59.4%61.1%
Operating margin20.6%23.2%22.2%27.4%28.3%28.0%26.8%28.2%32.7%33.4%
Net margin16.6%13.5%15.5%21.0%14.8%21.8%21.3%21.8%27.2%26.9%

Cash flow

ResMed| cash flow, annual
PeriodFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Operating cash flow$414.1M$505.0M$459.1M$802.3M$736.7M$351.1M$693.3M$1.40B$1.75B$1.81B
Capital expenditure$62.22M$62.58M$68.71M$95.33M$102.7M$134.8M$119.7M$99.46M$89.86M$156.3M
Free cash flow$351.8M$442.4M$390.3M$706.9M$634.0M$216.3M$573.6M$1.30B$1.66B$1.65B

Balance sheet and shares

ResMed| balance sheet and shares, annual
PeriodFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Cash and equivalents$821.9M$188.7M$147.1M$463.2M$295.3M$273.7M$227.9M$238.4M$1.21B$1.47B
Total debt$1.08B$281.5M$1.27B$1.30B$793.7M$917.5M$1.58B$873.9M$851.8M$825.9M
Shareholders' equity$1.96B$2.06B$2.07B$2.50B$2.89B$3.36B$4.13B$4.86B$5.97B$6.59B
Diluted shares142M144M144M146M146M147M147M148M147M146M
Dividends per share$1.32$1.40$1.48$1.56$1.56$1.68$1.76$1.92$2.12$2.40

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

ResMed| quarterly financial figures
PeriodQ2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026Q1 FY2027
Revenue$1.28B$1.29B$1.35B$1.34B$1.42B$1.43B$1.46B$1.41B
Revenue, year on year+10.3%+7.9%+10.2%+9.1%+11.0%+10.8%+8.6%+5.9%
Gross margin58.6%59.3%60.8%61.2%61.8%62.2%58.8%61.5%
Operating income$417.2M$426.3M$454.5M$446.5M$491.7M$499.8M$448.7M$453.0M
Net income$344.6M$365.0M$379.7M$348.5M$392.6M$398.7M$383.4M$418.4M
Diluted EPS$2.34$2.48$2.58$2.37$2.68$2.74$2.64$2.92
Free cash flow$288.0M$557.9M$508.2M$414.4M$311.2M$520.5M$403.5M$373.7M

Operating KPIs

The operating figures ResMed| reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

ResMed| operating KPIs
KPILatestPeriodChange on a yearRecent periods
Devices revenue$288.2Mquarter to 31 Mar 2026up 13.7%
Masks and other revenue$153.6Mquarter to 31 Mar 2026up 20.3%
Residential Care Software revenue$155.0Mquarter to 30 Sep 2026down 6.7%
United States revenue$3.6Bfiscal year to 30 Jun 2026up 8.4%
Rest of the World revenue$2.1Bfiscal year to 30 Jun 2026up 12.4%
Global revenue$1.4Bquarter to 31 Mar 2026up 10.8%
U.S., Canada and Latin America revenue$818.7Mquarter to 31 Mar 2026up 9.3%
Combined Europe, Asia and other markets revenue$441.8Mquarter to 31 Mar 2026up 15.9%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was ResMed|'s revenue in fiscal 2026?

$5.65 billion for fiscal year 2026 (the twelve months to 30 Jun 2026), as reported in its annual report.

What was ResMed|'s net income in fiscal 2026?

$1.52 billion for fiscal year 2026 (the twelve months to 30 Jun 2026).

What were ResMed|'s diluted earnings per share in fiscal 2026?

$10.43 for fiscal year 2026 (the twelve months to 30 Jun 2026).

What is ResMed|'s gross margin?

61.1% for fiscal year 2026 (the twelve months to 30 Jun 2026): gross profit divided by revenue.

What is ResMed|'s operating margin?

33.4% for fiscal year 2026 (the twelve months to 30 Jun 2026): operating income divided by revenue.

How much free cash flow did ResMed| generate in fiscal 2026?

$1.65 billion for fiscal year 2026 (the twelve months to 30 Jun 2026): operating cash flow less capital expenditure.

Where does ResMed|'s revenue come from?

In fiscal 2026, by segment: Total Sleep and Breathing Health $4.98B (88%), Residential Care Software $675.8M (12%), out of $5.65B in all, as stated in its annual report.

In the terminal

Twenty years of ResMed|'s figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans